Temporal trend in survival for chronic myelomonocytic leukemia in the US: a population-based study

References

• Itzykson R, Duchmann M, Lucas N, et al. CMML: clinical and molecular aspects. Int J Hematol. 2017;105(6):711–719. doi:10.1007/s12185-017-2243-z
   PubMed Web of Science ®Google Scholar
• Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol. 2020;95(1):97–115. doi:10.1002/ajh.25684
   PubMed Web of Science ®Google Scholar
• Geissler K, Jäger E, Barna A, et al. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): a representative and useful real-life data source for further biomedical research. Wien Klin Wochenschr. 2019;131(17–18):410–418. doi:10.1007/s00508-019-1526-1
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Stone RM, Al-Kali A, et al. Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15(1):60–87. doi:10.6004/jnccn.2017.0007
   PubMed Web of Science ®Google Scholar
• Solary E, Itzykson R. How I treat chronic myelomonocytic leukemia. Blood. 2017;130(2):126–136. doi:10.1182/blood-2017-04-736421
   PubMed Web of Science ®Google Scholar
• Liapis K, Kotsianidis I. Approaching first-line treatment in patients with advanced CMML: hypomethylating agents or cytotoxic treatment? Front Oncol. 2021;11:801524. doi:10.3389/fonc.2021.801524
   PubMed Web of Science ®Google Scholar
• Bewersdorf JP, Zeidan AM. Risk-adapted, individualized treatment strategies of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Cancers (Basel). 2021;13(7):1610. doi:10.3390/cancers13071610
   PubMed Web of Science ®Google Scholar
• Short NJ, Kantarjian H. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: past discoveries and future directions. Am J Hematol. 2022;97(12):1616–1626. doi:10.1002/ajh.26667
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–1803. doi:10.1002/cncr.21792
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440. doi:10.1200/JCO.2002.04.117
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232. doi:10.1016/S1470-2045(09)70003-8
   PubMed Web of Science ®Google Scholar
• Azacitdine FDA Package Insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/050974s034lbl.pdf
   Google Scholar
• Decitabine FDA Package Insert. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021790s021lbl.pdf
   Google Scholar
• Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118(14):3824–3831. doi:10.1182/blood-2011-05-352039
   PubMed Web of Science ®Google Scholar
• Wijermans PW, Rüter B, Baer MR, et al. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2008;32(4):587–591. doi:10.1016/j.leukres.2007.08.004
   PubMed Web of Science ®Google Scholar
• Fianchi L, Criscuolo M, Breccia M, et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an italian retrospective study. Leuk Lymphoma. 2013;54(3):658–661. doi:10.3109/10428194.2012.719617
   PubMed Web of Science ®Google Scholar
• Thorpe M, Montalvão A, Pierdomenico F, et al. Treatment of chronic myelomonocytic leukemia with 5-azacitidine: a case series and literature review. Leuk Res. 2012;36(8):1071–1073. doi:10.1016/j.leukres.2012.04.024
   PubMed Web of Science ®Google Scholar
• Adès L, Sekeres MA, Wolfromm A, et al. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine. Leuk Res. 2013;37(6):609–613. doi:10.1016/j.leukres.2013.01.004
   PubMed Web of Science ®Google Scholar
• Costa R, Abdulhaq H, Haq B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011;117(12):2690–2696. doi:10.1002/cncr.25759
   PubMed Web of Science ®Google Scholar
• Wong E, Seymour JF, Kenealy M, et al. Treatment of chronic myelomonocytic leukemia with azacitidine. Leuk Lymphoma. 2013;54(4):878–880. doi:10.3109/10428194.2012.730615
   PubMed Web of Science ®Google Scholar
• Drummond MW, Pocock C, Boissinot M, et al. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia. 2014;28(7):1570–1572. doi:10.1038/leu.2014.85
   PubMed Web of Science ®Google Scholar
• Tantravahi SK, Szankasi P, Khorashad JS, et al. A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. Leuk Lymphoma. 2016;57(10):2441–2444. doi:10.3109/10428194.2016.1138295
   PubMed Web of Science ®Google Scholar
• Santini V, Allione B, Zini G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018;32(2):413–418. doi:10.1038/leu.2017.186
   PubMed Web of Science ®Google Scholar
• Pleyer L, Germing U, Sperr WR, et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res. 2014;38(4):475–483. doi:10.1016/j.leukres.2014.01.006
   PubMed Web of Science ®Google Scholar
• Zeidan AM, Hu X, Long JB, et al. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: a large population-based study. Cancer. 2017;123(19):3754–3762. doi:10.1002/cncr.30814
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. Available from: www.seer.cancer.gov
   Google Scholar
• Duggan MA, Anderson WF, Altekruse S, et al. The surveillance, epidemiology, and end results (SEER) program and pathology: toward strengthening the critical relationship. Am J Surg Pathol. 2016;40(12):e94–e102. doi:10.1097/PAS.0000000000000749
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence – SEER Research Plus Data, 17 Registries, Nov 2021 Sub (2000–2019) – Linked To County Attributes – Time Dependent (1990–2019) Income/Rurality, 1969–2020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2022, based on the November 2021 submission [cited 2022 Nov 21]. Available from: www.seer.cancer.gov/seerstat
   Google Scholar
• Surveillance Research Program. National Cancer Institute SEER*Stat software –version 8.4.0.1 [cited 2022 Nov 21]. Available from: www.seer.cancer.gov/seerstat
   Google Scholar
• Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr. 1961;6:101–121.
   PubMedGoogle Scholar
• Henson DE, Ries LA. The relative survival rate. Cancer. 1995;76(10):1687–1688. doi:10.1002/1097-0142(19951115)76:10<1687::AID-CNCR2820761002>3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10. Bethesda, MD: End Results Evaluation Section, National Cancer Institute; 1959.
   Google Scholar
• Products – Life Tables – Homepage ( cdc.gov).
   Google Scholar
• Dickman PW, Coviello E. Estimating and modeling relative survival. Stata J. 2015;15(1):186–215. doi:10.1177/1536867X1501500112
   Web of Science ®Google Scholar
• Kirtane K, Lee SJ. Racial and ethnic disparities in hematologic malignancies. Blood. 2017;130(15):1699–1705. doi:10.1182/blood-2017-04-778225
   PubMed Web of Science ®Google Scholar
• American Cancer Society, Cancer Facts & Figures for African Americans 2019–2021. 2019. [cited 2022 Nov 21]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-facts-and-figures-for-african-americans/cancer-facts-and-figures-for-african-americans-2019-2021.pdf
   Google Scholar
• Siminoff LA, Ross L. Access and equity to cancer care in the USA: a review and assessment. Postgrad Med J. 2005;81(961):674–679. doi:10.1136/pgmj.2005.032813
   PubMed Web of Science ®Google Scholar
• Bhatnagar B, Kohlschmidt J, Mrózek K, et al. Poor survival and differential impact of genetic features of Black patients with acute myeloid leukemia. Cancer Discov. 2021;11(3):626–637. doi:10.1158/2159-8290.CD-20-1579
   PubMed Web of Science ®Google Scholar
• Bhatt VR, Shostrom V, Gundabolu K, et al. Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. Blood Adv. 2018;2(11):1277–1282. doi:10.1182/bloodadvances.2018019125
   PubMed Web of Science ®Google Scholar
• Pulte D, Redaniel MT, Jansen L, et al. Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica. 2013;98(2):222–229. doi:10.3324/haematol.2012.063602
   PubMed Web of Science ®Google Scholar
• Paulson K, Brazauskas R, Khera N, et al. Inferior access to allogeneic transplant in disadvantaged populations: a center for international blood and marrow transplant research analysis. Biol Blood Marrow Transplant. 2019;25(10):2086–2090. doi:10.1016/j.bbmt.2019.06.012
   PubMed Web of Science ®Google Scholar
• Byrne MM, Halman LJ, Koniaris LG, et al. Effects of poverty and race on outcomes in acute myeloid leukemia. Am J Clin Oncol. 2011;34(3):297–304. doi:10.1097/COC.0b013e3181dea934
   PubMed Web of Science ®Google Scholar
• Goksu SY, Ozer M, Goksu BB, et al. The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. Leuk Lymphoma. 2022;63(7):1651–1659. doi:10.1080/10428194.2022.2032034
   PubMed Web of Science ®Google Scholar
• Lesegretain A, Brunner A, King AJ, et al. Comparison of demographics, disease characteristics, and outcomes between Black and White patients with myelodysplastic syndromes: a population-based study. Leuk Res. 2023;125:107006. doi:10.1016/j.leukres.2022.107006
   PubMed Web of Science ®Google Scholar